MWC
AQST icon

MBM Wealth Consultants’s Aquestive Therapeutics AQST Stock Holding History

MBM Wealth Consultants’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,950
Closed -$70.3K – 138
2026
Q1 		$70.3K Hold
16,950
– – 0.02% 136
2025
Q4 		$109K Buy
+16,950
New +$106K 0.03% 110

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

MBM Wealth Consultants's AQST Position: Q2 2026 in Review

MBM Wealth Consultants sold out of Aquestive Therapeutics (AQST) in Q2 2026, closing a stake of 16,950 shares — an estimated $70.3K sold.

MBM Wealth Consultants first reported a position in AQST in Q4 2025 and held it in 2 quarters. The position peaked at $109K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • MBM Wealth Consultants reported no remaining Aquestive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MBM Wealth Consultants sold 16,950 Aquestive Therapeutics shares in Q2 2026, an estimated $70.3K.
  • MBM Wealth Consultants first reported a position in Aquestive Therapeutics in Q4 2025 and held it in 2 quarters.
  • MBM Wealth Consultants's Aquestive Therapeutics position peaked at $109K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on MBM Wealth Consultants's 13F filing for Q2 2026, filed 24 Jul 2026.